SG Americas Securities LLC Sells 220,135 Shares of Altimmune, Inc. (NASDAQ:ALT)

SG Americas Securities LLC lowered its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 86.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 34,436 shares of the company’s stock after selling 220,135 shares during the quarter. SG Americas Securities LLC’s holdings in Altimmune were worth $211,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Swiss National Bank bought a new position in Altimmune in the 1st quarter valued at $1,079,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Altimmune in the 1st quarter valued at $271,000. Sei Investments Co. bought a new position in Altimmune in the 1st quarter valued at $479,000. Commonwealth Equity Services LLC grew its position in Altimmune by 31.5% in the 1st quarter. Commonwealth Equity Services LLC now owns 79,945 shares of the company’s stock valued at $814,000 after acquiring an additional 19,172 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after acquiring an additional 335,444 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

Analysts Set New Price Targets

ALT has been the subject of several research reports. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, August 22nd. Finally, B. Riley reiterated a “buy” rating and issued a $20.00 target price on shares of Altimmune in a report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.80.

Insider Buying and Selling

In related news, Director David Drutz sold 16,011 shares of Altimmune stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the transaction, the director now directly owns 41,958 shares in the company, valued at approximately $289,510.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.10% of the stock is owned by corporate insiders.

Altimmune Stock Performance

Altimmune stock opened at $6.80 on Wednesday. The stock has a 50-day moving average of $6.74 and a two-hundred day moving average of $6.93. Altimmune, Inc. has a one year low of $2.09 and a one year high of $14.84. The stock has a market cap of $482.13 million, a PE ratio of -4.28 and a beta of 0.08.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The firm had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 24,778.97% and a negative return on equity of 53.09%. During the same quarter in the previous year, the company earned ($0.32) earnings per share. As a group, sell-side analysts predict that Altimmune, Inc. will post -0.54 EPS for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.